---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-122617"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:30:32.452032+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Liquidia faces new patent infringement claim over '327 patent added to PH-ILD suit

## Summary
- United Therapeutics amended complaint adds U.S. Patent No. 11,826,327, issued Nov 28, 2023.
- Patent covers inhaled treprostinil for PH-ILD; YUTREPIA label amendment triggers claim.
- Liquidia believes no 30-month stay applies because patent issued after original NDA filing.
- Case continues in U.S. District Court for Delaware; Liquidia vows vigorous defense.

## SEC filing metadata
- accession: 0001104659-23-122617
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923122617/0001104659-23-122617-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923122617/tm2331419d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-122617
- JSON: https://secwatch.observer/filing/0001104659-23-122617.json
- Plain text: https://secwatch.observer/filing/0001104659-23-122617.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.